Longer Duration of Treatment with ICIs Associated with a Higher Rate of Complete Response Among Patients with MMRd Cancers By Ogkologos - March 5, 2025 473 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a systematic review of published studies Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Palliative and Supportive Care for Children With Cancer: An Expert Perspective October 5, 2023 Toddler Hailed A Hero After He Saved His Family From Fire... January 28, 2022 The most important cancer research stories of 2022 December 14, 2022 FDA Grants Accelerated Approval to Repotrectinib for Adult and Paediatric Patients... July 8, 2024 Load more HOT NEWS Meeting Cancer Survivors’ Psychosocial Health Needs: A Conversation with Dr. Patricia... FDA Grants Accelerated Approval to fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic... Aromatase inhibitors cut breast cancer recurrence in younger patients Experts Think Medical Detection Dogs Could Be Trained To Sniff Out...
